Evidence map›Paper›PMID 7496932›Full record

ReviewClinical and diagnostic laboratory immunology1994

Role of human natural killer cells in health and disease.

T L Whiteside, R B Herberman

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Clinical and diagnostic laboratory immunology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00565305 (Quality of Life and Immunity During Breast Cancer Treatment), which is not on this map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00565305 nacompletednot on this mapstarted 2003, after this paper: background citation

Quality of Life and Immunity During Breast Cancer Treatment

TypeinterventionalSponsorUniversity of IowaRan2003 to 2009Enrolled150ConditionsBreast CancerArmsHealing Touch, Standard Treatment
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 172 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

T L WhitesidePittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213, USA.
R B Herberman
UPMC Hillman Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells, the CD3- CD56+ CD16+ subset of peripheral blood lymphocytes, have long been known to be involved in non-major histocompatibility complex-restricted natural immunity to virally infected and malignant target cells. The association of abnormalities in NK cell numbers or functions with a broad spectrum of human diseases has been more clearly defined in recent years as a result of the improved knowledge of NK cell physiology and advances in monitoring of NK cell functions in health and disease. The ability to reliably measure changes in NK activity and/or numbers during the course of disease or response to treatment has focused attention on the role of the NK cell in disease pathogenesis. The improved understanding of NK cell deficiency in disease has opened a way for therapies specifically designed to improve NK cell function. The therapeutic use of biologic response modifiers capable of augmenting NK cell activity in vivo and of adoptive transfer of highly enriched, activated autologous NK cells in diseases such as cancer and AIDS is being evaluated. The importance of NK cells in health and the consequences of NK cell deficiency or excess are likely to be more extensively monitored in the future.

Indexed as

Cytotoxicity, ImmunologicImmunity, InnateHumansImmunologic Deficiency SyndromesImmunotherapy, AdoptiveKiller Cells, NaturalNeoplasms

Identifiers

PMID7496932
PMCPMC368214
OpenAlexW2148665268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.